26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Giant Subependymoma Developed in a Patient with Aniridia: Analyses of PAX6 and Tumor-relevant Genes

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We observed an unusually large subependymoma in a female patient with congenital aniridia. To analyze the genetic mechanisms of tumorigenesis, we first examined the paired box 6 ( PAX6) gene using both tumor tissue and peripheral lymphocytes. Tumor suppressor activity has been proposed for PAX6 in gliomas, in addition to its well-known role in the eye development. Using genomic quantitative PCR and loss of heterozygosity analysis, we identified hemizygous deletions in the 5′-region of PAX6. In lymphocytes, the deletion within PAX6 spanned from between exons 6 and 7 to the 5′-upstream region of the gene, but did not reach the upstream gene, RNC1, which is reported to be associated with tumors. The subependymoma had an additional de novo deletion spanning from the intron 4 to intron 6 of PAX6, although we could not completely determine whether these two deletions are on the same chromosome or not. We also examined other potentially relevant tumor suppressor genes: PTEN, TP53 and SOX2. However, we detected no exonic mutations or deletions in these genes. Collectively, we speculate that the defect in PAX6 may have contributed to the extremely large size of the subependymoma, due to a loss of tumor suppressor activity in glial cell lineage.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Integrated detection and population-genetic analysis of SNPs and copy number variation.

          Dissecting the genetic basis of disease risk requires measuring all forms of genetic variation, including SNPs and copy number variants (CNVs), and is enabled by accurate maps of their locations, frequencies and population-genetic properties. We designed a hybrid genotyping array (Affymetrix SNP 6.0) to simultaneously measure 906,600 SNPs and copy number at 1.8 million genomic locations. By characterizing 270 HapMap samples, we developed a map of human CNV (at 2-kb breakpoint resolution) informed by integer genotypes for 1,320 copy number polymorphisms (CNPs) that segregate at an allele frequency >1%. More than 80% of the sequence in previously reported CNV regions fell outside our estimated CNV boundaries, indicating that large (>100 kb) CNVs affect much less of the genome than initially reported. Approximately 80% of observed copy number differences between pairs of individuals were due to common CNPs with an allele frequency >5%, and more than 99% derived from inheritance rather than new mutation. Most common, diallelic CNPs were in strong linkage disequilibrium with SNPs, and most low-frequency CNVs segregated on specific SNP haplotypes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

            Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express several genes typical of normal neural stem cells. One of them, SOX2, is a master gene involved in sustaining self-renewal of several stem cells, in particular neural stem cells. To investigate its role in the aberrant growth of glioblastoma, we silenced SOX2 in freshly derived glioblastoma tumor-initiating cells (TICs). Our results indicate that SOX2 silenced glioblastoma TICs, despite the many mutations they have accumulated, stop proliferating and lose tumorigenicity in immunodeficient mice. SOX2 is then also fundamental for maintenance of the self-renewal capacity of neural stem cells when they have acquired cancer properties. SOX2, or its immediate downstream effectors, would then be an ideal target for glioblastoma therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Danish Cancer Registry--history, content, quality and use.

              The Danish Cancer Registry is a population-based registry containing data on the incidence of cancer throughout Denmark since 1943. Reporting of cancer was made mandatory by administrative order in 1987. Details of individual cases of cancer are available according to the 7th revision of the International Classification of Diseases (ICD) for all years, and according to the ICD-O since 1978. A core data set is kept on each individual which includes date of birth, sex, date of cancer diagnosis, method of verification, date of death and cause of death. This paper describes the history of the registry, its data sources and its procedures, including quality control and access to data. Integration of both research activities and registration since the inception of the Registry has maintained the completeness and validity of the data for 1943-1996.
                Bookmark

                Author and article information

                Journal
                Brain Pathol
                bpa
                Brain Pathology (Zurich, Switzerland)
                Blackwell Publishing Ltd
                1015-6305
                1750-3639
                November 2010
                : 20
                : 6
                : 1033-1041
                Affiliations
                [1 ]simpleLaboratory for Molecular Psychiatry, RIKEN Brain Science Institute Saitama
                [2 ]simpleDepartment of Neurosurgery, Fukui Prefectural Hospital Fukui
                [3 ]simpleDepartment of Neurosurgery, Kanazawa University Hospital Ishikawa
                [4 ]simpleDepartment of Developmental Neurobiology, Tohoku University Graduate School of Medicine Sendai
                [5 ]simpleCREST, Japanese Science and Technology Agency Tokyo, Japan
                Author notes
                Motoko Maekawa, MD, PhD, Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan (E-mail: mmaekawa@ 123456brain.riken.jp ); Hironori Fujisawa, MD, PhD, Department of Neurosurgery, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui-city, Fukui 910-8526, Japan (E-mail: hfujisawa@ 123456room.ocn.ne.jp )
                [*]

                These three authors contributed equally to this work

                Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

                Article
                10.1111/j.1750-3639.2010.00406.x
                2991767
                20500513
                b7d7abff-a9d5-4885-ba1a-23d3a3539c0c
                Copyright © 2010 International Society of Neuropathology

                Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

                History
                : 28 January 2010
                : 26 April 2010
                Categories
                Research Articles

                Pathology
                tp53,pax6 deletion,loss of heterozygosity,pten,sox2,genomic quantitative pcr
                Pathology
                tp53, pax6 deletion, loss of heterozygosity, pten, sox2, genomic quantitative pcr

                Comments

                Comment on this article